February 28, 2024
NAFDAC Issues Warning Against Use Of Unapproved Diabetes Drug
News Today In the News

NAFDAC Issues Warning Against Use Of Unapproved Diabetes Drug

The National Agency for Food and Drug Administration and Control (NAFDAC has warned the public against the use of Glucozil, a herbal medicine for diabetes linked with the Ambrose Alli University Ekpoma, saying the batch in circulation is not approved.

The regulatory agency said the herbal medicine certificate of the product claimed to manage high blood sugar has expired since November 2022, without renewal. The active ingredients in Glucozil are also not known. The product claims to work by stimulating the production of insulin, the hormone that helps the body use glucose for energy. It also claims to have anti-inflammatory and antioxidant properties, which may help to protect the body from the damage caused by diabetes.

READ ALSO: NPA Renews Trade Facilitation Agreement With Customs To Boost Export

NAFDAC however noted that the product’s claims of treating, curing and preventing diabetes, benign prostatic hyperplasia, and detoxification were never approved for Glucozil as claimed in a publication earlier.

It also states that its records do not show that Ambrose Alli University is the manufacturer or the applicant of the product for which the Listing is no longer valid. It reiterated that it is crucial to exercise caution when interpreting health-related claims and refer to NAFDAC’s official communications channels for accurate updates and information

    • 6 months ago

    […] READ ALSO: NAFDAC Issues Warning Against Use Of Unapproved Diabetes Drug […]

Leave feedback about this

  • Quality
  • Price
  • Service


Add Field


Add Field
Choose Image
Choose Video